Dyax kills ecallantide early after duff PhII in drug-induced angioedema
This article was originally published in Scrip
Executive Summary
Dyax has discontinued a Phase II trial of its already approved kallikrein inhibitor, ecallantide, testing its utility in treating angiotensin-converting enzyme (ACE) inhibitor-induced angioedema after an interim analysis did not show a significant difference between the ecallantide-treated and placebo groups. Upon the news, the stock sank by 11.2%, to $1.90, but the shares later recovered slightly.